We cordially invite all the participants from all over the world to attend 2nd International Conference on Cell and Gene therapy during April 15-16, 2019 in Milan, Italy which includes prompt keynote presentations, Oral talks, Poster presentations, Young Research Forum, E-Poster presentation and Exhibitions.
Cell and Gene therapy Conference hosting presentations from editors of prominent referred journals, renowned active investigators and decision makers in the field of Genetics and many related field. Cell and Gene therapy 2019 Conference deals with the diagnosis, prevention, and treatment & therapies of diseases of the gene specific, organ specific including the latest techniques in current era.
Cell and Gene therapy 2019 is an extraordinary event designed for International medical health professionals like Immunologist, Oncologist, Neurologist, Genetic researchers and associated people of gene and cell research to facilitate the dissemination and application of research findings related to Cell and Gene therapy. The conference invites participants from all leading universities, clinical research institutions and diagnostic companies to share their research experiences on all aspects of this rapidly expanding field and thereby, providing a showcase of the latest techniques. Cell and Gene Therapy 2019 provides two days of robust discussions on methods and strategies related to management and quality improvement of Cell and Gene Therapy as well as explore new ideas and concepts on a global scale and the topics include Genomic Engineering, Biomarker, Advances in Cell and Gene Therapy, Immunogenetics & Transplantation, Regenerative Medicine and many related topics of gene and cell.
Welcome Message
We are delighted to invite you a new initiative, “2nd International Conference on Cell and Genetherapy” during April 15-16, 2019, going to be held in Milan, Italy.
Meeting invites you to the Conference on Cell and Gene therapy 2019 going to be held in April with the topic, “Cell and Gene therapy 2019” This international meet foresees several delegates including Keynote speakers, Oral presentations by prestigious speakers and publication presentations by understudies other than representatives around the globe. This gathering may be a mammoth occasion that makes a perfect stage to share aptitude tending to current advancements required in Cell and Gene Therapy.
Sessions & Tracks
- Cell Therapy
- Gene Therapy
- Stem Cell Therapies
- Cell Culture and Bioprocessing
- Tissue Science & Regenerative Medicine
- Clinical Trials on Cell & Gene Therapy
- Nano Therapy
- Advanced Gene Therapeutics
- Gene and Cell Therapy for Rare & Common Diseases
- Cell Science and Stem Cell Research
- Molecular Basis of Epigenetics
- Genetics and Stem Cell Biology
- Regulatory and Safety Aspects of Cell and Gene Therapy
- Markets & Future Prospects for Cell & Gene Therapy
- Cell Biology
- CHO cells
- Gene editing and CRISPR based technologies
- Genetics & Genomic Medicine
- Bioengineering Therapeutics
- Immunogenetics & Transplantation
- Biomarkers
Market Analysis
2nd International Conference on Cell & Gene therapy 2019 to be held during April 15-16, 2019 Milan, Italy with the theme of “Novel Innovations in Cell and Gene therapy” The scope of Gene Therapy Market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023. With the advancement in technology, the gene therapy market has transformed during the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer.
Scope: The Scope of the conference is to gather all the Doctors, Researchers, Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere. This Cell and Gene therapy Conference is the premier event focusing on understanding individual and organizational behavior and decision-making related to genetics and molecular biology, biotechnology, pharmaceuticals, medicals and academia.
Importance: Conference on Cell & Gene therapy is a much celebrated conference which basically deals with the latest research and developments in the sphere of Cell and molecular biology. This Conference will stipulate a errorless information to all the International mix of leading Research Scholars, and Scientists achieved eminence in their field of study, research academicians from the universities and research institutions, industrial research professionals and business associates along with Ph.D. Students to come and inform all the attendees about the latest scientific advancements on the respective sphere.
List of Gene Therapy Societies:
- American Society of Gene and Cell Therapy
- Australasian Gene and Cell Therapy Society
- Austrian Network for Gene Therapy
- British Society of Gene and Cell Therapy
- European Society of Gene and Cell Therapy
- Finnish Gene Therapy Society
- French Society of Cellular and Gene Therapy
- German Gene Therapy Society
- Japan Society of Gene Therapy
- Korean Society of Gene and Cell Therapy
- Netherlands Society of Gene and Cell Therapy
- Spanish Society of Gene and Cell Therapy
- Swedish Society for Gene and Cell Therapy
- Turkish Society of Gene & Cell Therapy
Organizing Committee
Henry M. Sobell completed his studies at Brooklyn Technical High School (1948-1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993).He is now retired and living in the Adirondacks in New York, USA.
Research Interest
Anti-Aging, Global Health and Chronic Disease
Wilhelm Gerdes
Wilhelm Gerdes has completed his PhD from Eberhard-Karls-Universit ät Tübingen, Germany. He was CBO of Cell Copedia GmbH. He was CFO of Magna Diagnostics. At present he is working as a BDM at IBA Lifesciences.
Research Interest
Stem Cell Research
Theresa A Deisher
Theresa A. Deisher obtained her Ph.D. in Molecular and Cellular Physiology from Stanford University School of Medicine. An expert in adult stem cell research, she is the first person to discover adult pluripotent stem cells. She is an inventor of over 35 issued US/Japan patents, whose discoveries have led to clinical trials of fibroblast growth factor 18 for osteoarthritis and cartilage repair, and for Factor XIII for surgical bleeding. Prior to founding AVM Biotechnology, she worked at leading biotechnology companies including Genentech, Repligen, ZymoGenetics, Immunex and Amgen as their principal scientist and R&D Vice President. She has had extensive scientific and management experience in the commercial biotechnology field, including: • Genentech 1988-1990 • Repligen 1993-1995 – Hematopoietic Stem Cell Chemoattractants • ZymoGenetics 1995-2000 – Adult Cardiac Stem Cell; Mesodermal – Derived Stem Cell; VSEL Very Small Embryonic-Like Stem • Immunex/Amgen 2000-2006 – Derivation of Embryonic-Like Stem Cells from Human Cord Blood. She is a frequent lecturer on stem cell issues and an active member of ASH (The American Society of Hematology) and ASCO (ASCO: American Society of Clinical Oncology)
Research Interest
Stem Cell Research
Damian Marshall
Damian Marshall is the head of analytical development for the Cell and Gene Therapy Catapult and has almost 20 years of industrial gained working for SME’s and large companies. He leads a team of ~30 scientists working with a wide range of therapy developers helping to de-risk their route to commercialisation. This is achieved through advanced product characterisation, helping companies to manage sources of variability and gain a high level of products and process knowledge. His team is also supporting the development of new adaptive manufacturing approaches by integrating technologies to allow real-time product monitoring and enable feedback control during product manufacture.
Research Interest
Anti-Aging, Global Health and Chronic Disease
Limo Chen
Finished postdoctoral training at Baylor College of Medicine (Immunology) and Harvard Medical School (Translational Cancer Research),presently working at Department of Immunology at MD Anderson focusing on tumor immunology.
Research Interest
Anti-Aging, Global Health and Chronic Disease
Dr. Ian Martins
Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc) with an H-index of 64, (ResearchGate STATs (27), Scopus Author ID: 7103152779/Mendeley STATS (21), UWA Research Repository (16). Scientist for The Science Advisory Board (USA) and an Academic with Academia.edu. The citations past 27 years have accumulated to >4584. Ian James Martins – Semantic Scholar https://www.semanticscholar.org/author/Ian-James-Martins/5258067. Semantic Scholar profile for Ian James Martins, with fewer than 50 highly influential citations RESEARCHGATE ANALYSIS: Ian J Martins | Ph D | Centre of Excellence for Alzheimer’s Disease …https://www.researchgate.net/profile/Ian_Martins2 under Ian James Martins’ name places publication RG score (> 96%) of international SCIENTISTS. ORCID CONNECTING RESEARCHER: Editorial Team www.macrothink.org/journal/index.php/jfs/about/editorialTeamBio/13511 Editorial Team. Ian James Martins. Ian James Martins Mail • http://orcid.org/0000-0002-2390-1501. Edith Cowan University, Australia. Prestigious Recognition of Lifetime Membership by International Agency for Standards and Ratings as Fellow for Diabetes, Medical Science (Nutrition). Winner (World Academic Championship -2017) in Diabetes and Medical Science (Nutrition). Certificates from various international conferences have been received in relation to anti-aging, health and disease. Keynote addresses at, Biomedicine 2018 (Osaka, Japan), Global Experts Meeting on Diabetes, Hypertension, Metabolic Syndrome 2018 (Melbourne, Australia), Immunology World 2018 (Amsterdam, Netherlands), Laboratory Medicine 2018 (Berlin, Germany), Innovate Pharma 2017 (Sydney, Australia), Innovate Neurology 2017(Sydney, Australia) World Diabetes and Endocrinology Summit-2017 (Dubai), Pharmacology and Ethnopharmacology 2016 (Chicago, USA) and AGHC 2016 (1st Plenary Speaker, Kaohsiung, Taiwan). Chair/Co-chair Sessions on Laboratory management, Cytogenetics, Clinical Microbiology, Diagnostic Laboratory Medicine etc, 13th Interantional Conference on Laboratory Medicine and Pathology, Berlin, Germany, June 25-26, 2018, Chairing Sessions on Vaccinology, Immunopathology, Immunotherapy, Immune Proteomics, Cancer and Tumour Oncology, 7th World Congress on Immunology, Amsterdam, Netherlands, April 19-20, 2018, Chair, Pipeline 1: Biotherapeutics for Diseases, Bit’s 2nd International Congress of Biotherapy-2018 (Programme Committee Member), Chair, Innovate Conferences 2017, Chair/Co-Chair at congress World Gene Convention-2016 (Shanghai, China, Pharmacology and Ethanopharmacology 2016 (Chicago, USA), Annual World Congress of Diabetes-2014 (Haikou, China), World Gene Convention-2014 (Haikou, China). Research Activity Statistics have been provided by Publons with comparison to other researchers. Ian James Martins is now in the 98th percentile as assessed for Publons users by merit. Dr Ian Martins is a reviewer for approx. 47 journals over the past 5 years.
Research Interest
Anti-Aging, Global Health and Chronic Disease
Nadia Benkirane Jessel
Dr. Nadia Benkirane is Research director and head of the “ Osteoarticular and Dental regenerative Nanomedicine” laboratory, at INSERM (French National Institute for Health and Medical Research), UMR 1109, Strasbourg, France. She was leader of “Active Biomaterials and Tissue Engineering” team INSERM 977. She received her Ph.D. from University Louis Pasteur, ULP, Strasbourg, France for the work on Development of pseudopeptides as synthetic vaccines. Dr. Jessel (Benkirane) then held a postdoctoral position in collaboration with the Institut Pasteur, Paris, France, working on Immunotherapy HIV, and another postdoctoral position on the application of modified peptides as vaccines against FMDV (Plum Island Animal Disease Center, ARS, USDA, Greenport, NY 11944-0848, USA). She joined the INSERM U595 in 2002 as a post-doc, and received the diploma to direct the research (HDR) in 2004. Dr. Jessel got the permanent position (CR1) in the INSERM 595 laboratory in 2004 and Research Director (DR2) position in the INSERM 977 and head of “active Biomaterials and Tissue Engineering team from 2009 until 2012). Currently Research Director (DR1) in the INSERM UMR 1109 (Osteoarticular and Dental Regenerative Nanomedicine” and heads the team. Dr. Jessel possesses expertise in diverse fields of molecular and cellular biology, immunochemistry, tissue engineering and biomedical engineering. In the last 10 years, she focused her research on the bio-functionalization of multilayered polyelectrolyte architectures with emphasis on the use of these architectures to induce specific cellular responses and gain control over cell proliferation and differentiation. Dr. Benkirane-Jessel have 138 publications (h index: 36) with peer-reviewed publications in high impact factor journals (Proc. Nat. Acad. Sci. USA; Adv. Mater.; Adv. Funct. Mater.; Small; Nanoletters, Biomaterials, ACS Nano), 5 chapters reviews and 5 international patents, she is a regular referee for a number of scientific journals (Nature nanotechnology, Nature Materials, ACS nano, Biomaterials, Nanoletters…). She is under the contract (Interface INSERM/Clinic 2008-2013) and she got also “Prime d’Excellence Scientifique” from the INSERM, 2010-2014 and the PEDR from the INSERM on 2016 for 4 years.
Research Interest
Anti-Aging, Global Health and Chronic Disease
Jacopo Meldolesi
MD cum laude (1962), Assistant and then Associate Professor at the University of Milan (1965-1980), he has been post-doc in the lab of the Nobel Graduate George E. Palade at the Rockefeller University of New York (1968-1970). Professor of General Pharmacology at the University of Milan (1981-1999) and then at the Vita-Salute San Raffaele University of Milan, he is an Emeritus since November 2010.
Research Interest
Anti-Aging, Global Health and Chronic Disease
Alexander Birbrair
Dr. Alexander Birbrair started his scientific career from B.S. in Biomedical Sciences from Universidade Estadual de Santa Cruz, UESC, Ilheus, Brazil. He completed his Ph.D. in Neurosciences Program, particularly in the field of Stem Cell Biology, from Wake Forest School of Medicine, Winston-Salem, NC, USA. Dr. Birbrair received his Post-Doctoral Degree from Albert Einstein College of Medicine, Bronx, NY, USA in Stem Cell Biology and joined as a Professor at Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil in 2016. He is a recipient of several notable awards and honours, which includes, Gordon A. Melson Outstanding Doctoral Student Award for 2015 and Editor’s choice Award in Journal of Gerontology Biological Sciences Volume 69 Issue 12 December 2014 for the manuscript “Human Slow Troponin T (TNNT1) Pre-mRNA Alternative Splicing is An Indicator of Skeletal Muscle Response to Resistance Exercise in Older Adults.” by Zhang T, Choi SJ, Wang ZM, Birbrair A, Messi ML, Jin J-P, Marsh AP, Nicklas B, and Delbono O. He is an active member of American Heart Association, Western NC Chapter of the Society for Neuroscience and International Society for Stem Cell Research with more than 30 publications in peer-reviewed journals and serves as an ad hoc reviewer for 14 Journals related to pathology and stem cell biology.
Research Interest
Anti-Aging, Global Health and Chronic Disease
Giuseppe Ronzitti
Dr. Ronzitti is group leader at Genethon. His main interest is the development of adeno-associated virus (AAV)-based gene therapies for rare disorders. In 2013, he arrived at Genethon as a post-doc supervised by Dr. Mingozzi to develop a gene therapy approach for Crigler-Najjar, a metabolic syndrome. This approach is now being translated in the clinic and the first patient will be injected this year.
Research Interest
Gene Therapy
Mitchell Sanders
Mitchell Sanders has over 30 years of experience in cell biology, animal models and clinical product development in advanced wound care. He has produced over 12 peer-reviewed publications and 27 worldwide patents in medical device, therapeutics, and in vitro diagnostics. Mitch is an expert in clinical and translational research and is a reviewer for the Wound Healing Society (WRR), Wounds International, Tissue Engineering, CIMIT, MassVentures, MIT, WPI, Tech Sandbox, Piranha Pond, SBANE and the Venture Forum.
Research Interest
Cell Biology
Address: NOVOTEL Milano Linate Aeroporto Hotel
Via Mecenate, 121, 20138 Milano MI, Italy
Source Link: http://celltherapycongress.alliedacademies.com/
